{"id":"023a8c4f-cbb8-593a-a702-660005cfdc91","stable_key":"5d8e27d8-6a74-5560-827f-3f90908bbc34:ala-ms-phase2-proteinuria","predicate":"associated_with","statement":"Proteinuria during ALA treatment prompted closer urine monitoring in the phase 2 trial; discontinuation was higher with ALA.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"21e93b03-c18e-5d81-9154-7b58435a0559","mechanism_event_label":"The trial identified a kidney-related safety signal as well as tolerability concerns.","subject":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"object":{"id":"8c8e2ef0-1ee6-5b83-be82-a89a65793127","slug":"progressive-ms-proteinuria","display_name":"Proteinuria during progressive-MS trial treatment","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"21e93b03-c18e-5d81-9154-7b58435a0559","stable_key":"5d8e27d8-6a74-5560-827f-3f90908bbc34:ala-ms-phase2-proteinuria-event","event_type":"observed_intervention","label":"The trial identified a kidney-related safety signal as well as tolerability concerns.","description":"Proteinuria during ALA treatment prompted closer urine monitoring in the phase 2 trial; discontinuation was higher with ALA.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8c8e2ef0-1ee6-5b83-be82-a89a65793127","slug":"progressive-ms-proteinuria","display_name":"Proteinuria during progressive-MS trial treatment","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ala-research/41397213.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba\", \"start_char\": 0, \"end_char\": 3010, \"text_sha256\": \"7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral ALA 1200 mg/day for 24 months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Primary timed-walking result was null; imaging interpretation complicated by T2 lesion volume and differential discontinuation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The trial identified a kidney-related safety signal as well as tolerability concerns.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"115 participants, 54 ALA and 61 placebo","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5eaeb967-f065-5338-b422-8a8b3fe8f644","evidence_kind":"source_excerpt","locator":"Lines 1287-1298","start_line":1287,"end_line":1298,"excerpt":"### ala-ms-phase2-proteinuria\nProteinuria during ALA treatment prompted closer urine monitoring in the phase 2 trial; discontinuation was higher with ALA.\nCondition category: normal\nnutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The trial identified a kidney-related safety signal as well as tolerability concerns.\norganism: Human\ntissue_or_cell_type: 115 participants, 54 ALA and 61 placebo\nexperimental_model: Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue\nlimitations: Primary timed-walking result was null; imaging interpretation complicated by T2 lesion volume and differential discontinuation.\nexposure: Oral ALA 1200 mg/day for 24 months\nevidence_span: {\"source_cache\": \"artifacts/ala-research/41397213.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba\", \"start_char\": 0, \"end_char\": 3010, \"text_sha256\": \"7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba\"}\n[ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454","model_system":"Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d8afa8c2-ced9-5b28-90ca-2ac120ec7202","stable_key":"import-5d8e27d8-6a74-5560-827f-3f90908bbc34","title":"Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"611da198ab85a272eb26b64ee330ef6d1a762853a8481f3191c4acfca9f3cf3d","revision_id":"618b4ce6-3157-5222-8325-408064be5ea5","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}